Sort
21,453 grants matching “tuberculosis”
N.J. MEDICAL SCHOOL GLOBAL TUBERCULOSIS INSTITUTE REGIONAL TRAINING & MEDICAL CON
$1,068,072Lee Reichman · Rbhs-New Jersey Medical School · U52 · FY2014 · PS
Integrated Care Clinics for IDUs in India: a cluster randomized trial
$1,068,055Gregory M Lucas · Johns Hopkins University · R01 · FY2015 · DA
Development of a novel adjuvanted Th1- and Th17-inducing subunit TB Vaccine
$1,067,980Shabaana A. Khader · University Of Chicago · R33 · FY2025 · AI
Advanced Mass Spectrometry Facility
$1,067,912David Anderson · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIC · FY2010 · DK
Phase 2 Study of the Efficacy and Safety of ORC-13661 for the Prevention of Ototoxicity in Patients Receiving Intravenous Amikacin for Treatment of Non-Tuberculous Mycobacterium Infection
$1,067,890Kevin Loring Winthrop · Oregon Health & Science University · U01 · FY2024 · DC
Optimization and preclinical development of a TB Multiple Antigen Presenting System (MAPS) vaccine
$1,067,677Richard Malley · Boston Children'S Hospital · R01 · FY2020 · AI
N.J. MEDICAL SCHOOL GLOBAL TUBERCULOSIS INSTITUTE REGIONAL TRAINING & MEDICAL CON
$1,067,608Alfred Lardizabal · Rbhs-New Jersey Medical School · U52 · FY2015 · PS
Efficacy and cost of HAART DOT in methadone clinics
$1,067,167Albert Einstein Col Of Med Yeshiva Univ · R01 · FY2005 · DA
UIC: In vitro In vivo Mtb Pharmacology
$1,066,689Scott G. Franzblau · Global Alliance For Tb Drug Development · U19 · FY2021 · AI
PRECLINICAL VALIDATION OF A NOVEL DRUG LEAD TO TREAT TUBERCULOSIS
$1,066,074The University Of Queensland · · FY2018 · Department of the Army
Collaborative African Genomics Network (CAfGEN)
$1,065,022Mogomotsi Sandy Matshaba · Botswana Baylor Child/Clincal Ctr/Excell · U54 · FY2017 · AI
TUBERCULOSIS ELIMINATION AND LABORATORY
$1,064,329Maureen E Murphy · Ohio State Department Of Health · U52 · FY2006 · PS
Mouse models for paucibacillary persistence
$1,061,923Sabine Ehrt · Weill Medical Coll Of Cornell Univ · U19 · FY2015 · AI
PROgression of Tuberculosis infECTion in young children living with and without HIV: the PROTECT study
$1,061,038Adithya Cattamanchi · University Of California-Irvine · R01 · FY2025 · AI
Tuberculosis Research Unit
$1,060,900W. Henry Henry Boom · Case Western Reserve University · N01 · FY2009 · AI
Point-of-care C-reactive protein-based tuberculosis screening in people living with HIV: a randomized trial
$1,060,388Christina Yoon · University Of California, San Francisco · R33 · FY2022 · HL
Evaluation of new diagnostics for incident, active and recurrent TB (ENDx-Tb)
$1,059,114Gerhard Walzl · Stellenbosch University · U01 · FY2025 · AI
Oxadiazole Inhibitors of Non-Stop Ribosome Rescue to treat MDR Neisseria gonorrhoeae
$1,058,081Zachary David Aron · Microbiotix, Inc · R01 · FY2020 · AI
AIDS International Training and Research Program (AITRP)
$1,057,030Arthur L. Reingold · University Of California Berkeley · D43 · FY2007 · TW
Point-of-care C-reactive protein-based tuberculosis screening in people living with HIV: a randomized trial
$1,056,953Christina Yoon · University Of California, San Francisco · R33 · FY2023 · HL
CENTER FOR AIDS RESEARCH (CFAR)
$1,056,731Case Western Reserve University · P30 · FY2001 · AI
Aurum Clinical Trials Unit
$1,056,434Gavin John Churchyard · Aurum Institute Npc · UM1 · FY2021 · AI
Development of Vaccines to Prevent Tuberculosis
$1,056,433Robert A Seder · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
India International Center for Excellence in Research
$1,056,353Thomas Nutman · National Institute Of Allergy And Infectious Diseases · ZIA · FY2013 · AI
Terry Beirn CPCRA Clinical Trials Unit
$1,055,836Fred M Gordin · George Washington University · UM1 · FY2015 · AI